PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
68.26
ESG score 1.1-1.2x Biotechnology median of 59.72. Philip Fisher would examine if superior ESG practices support long-term growth and stakeholder loyalty.
56.97
Environmental score near Biotechnology median of 56.97. David Dodd would investigate if industry-standard environmental practices adequately address climate risks.
81.13
Social score exceeding 1.2x Biotechnology median of 63.30. Joel Greenblatt would verify if this social leadership translates to employee productivity and customer loyalty advantages.
66.69
Governance score 1.1-1.2x Biotechnology median of 60.75. Philip Fisher would examine if superior governance practices support long-term value creation.